Menu
← Oncology Approval Tracker
FDA DECISION ·
Opdivo + Yervoy
nivolumab plus ipilimumab · Bristol Myers Squibb
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
First-line nivolumab with ipilimumab for adults with unresectable advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
LAMPGEN ANALYSIS
Why it matters
The dual-checkpoint regimen offers a first-line option that does not use cytotoxic chemotherapy.
What research teams should watch
Identify the regimen separately from nivolumab with chemotherapy and plan follow-up for dual-checkpoint toxicities.
PRIMARY RECORDS